Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CBX7 | O95931 | 3/20 | 0.48 |
| ▸ | CDYL2 | Q8N8U2 | 3/20 | 0.48 |
| ▸ | CDYL | Q9Y232 | 3/20 | 0.48 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6157272 | 0.82 | PDE4B (0.49) | PDE4BMAPTALDH1A1 | |
| SCHEMBL6157282 | 0.82 | PDE4B (0.49) | PDE4BMAPTALDH1A1 | |
| SCHEMBL11106554 | 0.78 | ALDH1A1 (0.62) | PDE4BCYP3A4CYP2C19MAPTCYP1A2 | |
| SCHEMBL10832384 | 0.77 | ALDH1A1 (0.56) | PDE4BCYP3A4CYP2C19MAPTCYP1A2 | |
| SCHEMBL2191407 | 0.76 | KMT2A (0.56) | CYP2C19MAPTALDH1A1POLBCYP2C9 | |
| SCHEMBL16533307 | 0.74 | ALDH1A1 (0.50) | CYP3A4CYP2C19MAPTCYP1A2ALDH1A1 | |
| SCHEMBL5563554 | 0.74 | ALDH1A1 (0.55) | PDE4BCYP3A4CYP2C19MAPTCYP1A2 | |
| SCHEMBL16533322 | 0.73 | ALDH1A1 (0.47) | CYP3A4CYP2C19MAPTCYP1A2ALDH1A1 | |
| SCHEMBL4281747 | 0.73 | HSP90AA1 (0.56) | ALDH1A1 | |
| SCHEMBL7314475 | 0.73 | PDE4B (0.47) | PDE4BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0819123-B1 | 1,3-DIHYDRO-1-(PHENYLALKENYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKINE INHIBITING ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-12 | — | — | EP | disclosed |
| EP-0832071-B1 | 1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKININ INHIBITING ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2005-09-28 | — | — | EP | disclosed |
| US-6403805-B1 | SUCH AS 1-((1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL) CYCLOPROPYL)METHYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE FOR ALLERGIES, ATOPIC AND INFLAMMATORY DISEASES WHEREIN ACTIVITY OF PHOSPHODIESTERASE IS ALTERED | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-06-11 | — | — | US | disclosed |
| US-20020068830-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2002-06-06 | — | — | US | disclosed |
| EP-0819122-B1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2002-03-06 | — | — | EP | disclosed |
| US-5994376-A | PHOSPHODIESTERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-11-30 | — | — | US | disclosed |
| US-5952510-A | ENZYME INHIBITOR AS ANTIALLERGENS, ANTIINFLAMMATORY AGENT TREATING INFLAMMATION DISEASES, SKIN DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BG) | 1999-09-14 | — | — | US | disclosed |
| US-5869515-A | TREATING ASTHMATIC OR ATOPIC DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-02-09 | — | — | US | disclosed |
| EP-0832071-A1 | 1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKININ INHIBITING ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-04-01 | — | — | EP | disclosed |
| EP-0819122-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031487-A1 | 1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKININ INHIBITING ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-10-10 | — | — | WO | disclosed |
| WO-1996031485-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068830-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES | HRH2, CBR1, HRH1 | PDE4B 71/4885CYP3A4 387/4885CYP2C19 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.